(Q37937699)

25 August 2017

1 reference

title

Bortezomib for previously untreated multiple myeloma (English)

1 reference

25 August 2017

Michel Delforge

1

1 reference

25 August 2017

language of work or name

English

0 references

publication date

23 September 2011

1 reference

Expert Opinion on Pharmacotherapy

25 August 2017

published in

1 reference

25 August 2017

volume

12

1 reference

25 August 2017

issue

16

1 reference

25 August 2017

page(s)

2553-2564

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.622266

25 August 2017

1 reference

Autologous hematopoietic stem-cell transplantation for multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.622266

Antitumor activity of thalidomide in refractory multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.622266

Bortezomib plus melphalan and prednisone for initial treatment of multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.622266

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.622266

The role of the ubiquitin-proteasome pathway in apoptosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.622266

The proteasome: structure, function, and role in the cell

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.622266

Approval summary for bortezomib for injection in the treatment of multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.622266

Velcade: U.S. FDA approval for the treatment of multiple myeloma progressing on prior therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.622266

NF-kappaB in cancer: from innocent bystander to major culprit

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.622266

Biologic sequelae of nuclear factor-kappaB blockade in multiple myeloma: therapeutic applications

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.622266

Proteasome inhibitors induce a terminal unfolded protein response in multiple myeloma cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.622266

Bortezomib induces canonical nuclear factor-kappaB activation in multiple myeloma cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.622266

How the cyclin became a cyclin: regulated proteolysis in the cell cycle

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.622266

Protease inhibitor-induced apoptosis: accumulation of wt p53, p21WAF1/CIP1, and induction of apoptosis are independent markers of proteasome inhibition

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.622266

Proteasome inhibitors in the treatment of multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.622266

Molecular mechanisms mediating antimyeloma activity of proteasome inhibitor PS-341.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.622266

Anti-angiogenic effect of bortezomib in patients with multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.622266

Bone marrow microenvironment and the identification of new targets for myeloma therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.622266

Aggresome induction by proteasome inhibitor bortezomib and alpha-tubulin hyperacetylation by tubulin deacetylase (TDAC) inhibitor LBH589 are synergistic in myeloma cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.622266

Combinatorial efficacy of anti-CS1 monoclonal antibody elotuzumab (HuLuc63) and bortezomib against multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.622266

Inhibition of interleukin-6 signaling with CNTO 328 enhances the activity of bortezomib in preclinical models of multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.622266

Proteasome inhibitors in the clinical setting: benefits and strategies to overcome multiple myeloma resistance to proteasome inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.622266

Increased bone mineral density in a subset of patients with relapsed multiple myeloma who received the combination of bortezomib, dexamethasone and zoledronic acid

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.622266

Home administration of bortezomib: making a difference to myeloma patients' lives

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.622266

Pharmacokinetic and pharmacodynamic study of two doses of bortezomib in patients with relapsed multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.622266

Prospective comparison of subcutaneous versus intravenous administration of bortezomib in patients with multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.622266

Subcutaneous versus intravenous administration of bortezomib in patients with relapsed multiple myeloma: a randomised, phase 3, non-inferiority study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.622266

Human metabolism of the proteasome inhibitor bortezomib: identification of circulating metabolites

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.622266

Effect of the cytochrome P450 2C19 inhibitor omeprazole on the pharmacokinetics and safety profile of bortezomib in patients with advanced solid tumours, non-Hodgkin's lymphoma or multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.622266

Effect of the CYP3A inhibitor ketoconazole on the pharmacokinetics and pharmacodynamics of bortezomib in patients with advanced solid tumors: a prospective, multicenter, open-label, randomized, two-way crossover drug-drug interaction study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.622266

Bortezomib in recurrent and/or refractory multiple myeloma. Initial clinical experience in patients with impared renal function

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.622266

Renal impairment in patients with multiple myeloma: a consensus statement on behalf of the International Myeloma Working Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.622266

Activity and safety of bortezomib in multiple myeloma patients with advanced renal failure: a multicenter retrospective study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.622266

Bortezomib and EGCG: no green tea for you?

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.622266

Ascorbic acid inhibits antitumor activity of bortezomib in vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.622266

Phase I trial of the proteasome inhibitor PS-341 in patients with refractory hematologic malignancies

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.622266

A phase 2 study of bortezomib in relapsed, refractory myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.622266

A phase 2 study of two doses of bortezomib in relapsed or refractory myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.622266

Bortezomib or high-dose dexamethasone for relapsed multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.622266

Bortezomib in combination with intermediate-dose dexamethasone and continuous low-dose oral cyclophosphamide for relapsed multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.622266

Randomized phase III study of pegylated liposomal doxorubicin plus bortezomib compared with bortezomib alone in relapsed or refractory multiple myeloma: combination therapy improves time to progression

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.622266

Bortezomib in combination with pegylated liposomal doxorubicin and thalidomide is an effective steroid independent salvage regimen for patients with relapsed or refractory multiple myeloma: results of a phase II clinical trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.622266

Multicenter, phase I, dose-escalation trial of lenalidomide plus bortezomib for relapsed and relapsed/refractory multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.622266

Importance of achieving a complete response in multiple myeloma, and the impact of novel agents

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.622266

Superiority of thalidomide and dexamethasone over vincristine-doxorubicindexamethasone (VAD) as primary therapy in preparation for autologous transplantation for multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.622266

Multicenter, randomized, double-blind, placebo-controlled study of thalidomide plus dexamethasone compared with dexamethasone as initial therapy for newly diagnosed multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.622266

Single-agent bortezomib in previously untreated multiple myeloma: efficacy, characterization of peripheral neuropathy, and molecular correlations with response and neuropathy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.622266

Bortezomib therapy alone and in combination with dexamethasone for previously untreated symptomatic multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.622266

Bortezomib plus dexamethasone is superior to vincristine plus doxorubicin plus dexamethasone as induction treatment prior to autologous stem-cell transplantation in newly diagnosed multiple myeloma: results of the IFM 2005-01 phase III trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.622266

Phase II trial of combination therapy with bortezomib, pegylated liposomal doxorubicin, and dexamethasone in patients with newly diagnosed myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.622266

Bortezomib, doxorubicin and dexamethasone (PAD) front-line treatment of multiple myeloma: updated results after long-term follow-up

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.622266

Bortezomib as induction before autologous transplantation, followed by lenalidomide as consolidation-maintenance in untreated multiple myeloma patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.622266

Cyclophosphamide, bortezomib and dexamethasone induction for newly diagnosed multiple myeloma: high response rates in a phase II clinical trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.622266

DSMM XI study: dose definition for intravenous cyclophosphamide in combination with bortezomib/dexamethasone for remission induction in patients with newly diagnosed myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.622266

Bortezomib with thalidomide plus dexamethasone compared with thalidomide plus dexamethasone as induction therapy before, and consolidation therapy after, double autologous stem-cell transplantation in newly diagnosed multiple myeloma: a randomised p

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.622266

Phase 2 study of two sequential three-drug combinations containing bortezomib, cyclophosphamide and dexamethasone, followed by bortezomib, thalidomide and dexamethasone as frontline therapy for multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.622266

Sustained complete remissions in multiple myeloma linked to bortezomib in total therapy 3: comparison with total therapy 2.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.622266

Lenalidomide, bortezomib, and dexamethasone combination therapy in patients with newly diagnosed multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.622266

Mobilization in myeloma revisited: IMWG consensus perspectives on stem cell collection following initial therapy with thalidomide-, lenalidomide-, or bortezomib-containing regimens

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.622266

Stem cell collection in patients with de novo multiple myeloma treated with the combination of bortezomib and dexamethasone before autologous stem cell transplantation according to IFM 2005-01 trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.622266

Bortezomib and high-dose melphalan as conditioning regimen before autologous stem cell transplantation in patients with de novo multiple myeloma: a phase 2 study of the Intergroupe Francophone du Myelome (IFM).

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.622266

Major tumor shrinking and persistent molecular remissions after consolidation with bortezomib, thalidomide, and dexamethasone in patients with autografted myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.622266

Oral melphalan, prednisone, and thalidomide in elderly patients with multiple myeloma: updated results of a randomized controlled trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.622266

Melphalan and prednisone plus thalidomide versus melphalan and prednisone alone or reduced-intensity autologous stem cell transplantation in elderly patients with multiple myeloma (IFM 99-06): a randomised trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.622266

Efficacy of melphalan and prednisone plus thalidomide in patients older than 75 years with newly diagnosed multiple myeloma: IFM 01/01 trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.622266

Phase III study of the value of thalidomide added to melphalan plus prednisone in elderly patients with newly diagnosed multiple myeloma: the HOVON 49 Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.622266

Melphalan and prednisone plus thalidomide or placebo in elderly patients with multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.622266

Superior outcomes associated with complete response in newly diagnosed multiple myeloma patients treated with nonintensive therapy: analysis of the phase 3 VISTA study of bortezomib plus melphalan-prednisone versus melphalan-prednisone

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.622266

Bortezomib plus melphalan and prednisone compared with melphalan and prednisone in previously untreated multiple myeloma: updated follow-up and impact of subsequent therapy in the phase III VISTA trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.622266

Bortezomib-melphalan-prednisone-thalidomide followed by maintenance with bortezomib-thalidomide compared with bortezomib-melphalan-prednisone for initial treatment of multiple myeloma: a randomized controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.622266

Genetic abnormalities and survival in multiple myeloma: the experience of the Intergroupe Francophone du Myélome.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.622266

Bortezomib plus dexamethasone induction improves outcome of patients with t(4;14) myeloma but not outcome of patients with del(17p).

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.622266

Light chain-induced acute renal failure can be reversed by bortezomib-doxorubicin-dexamethasone in multiple myeloma: results of a phase II study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.622266

Risk factors and kinetics of thrombocytopenia associated with bortezomib for relapsed, refractory multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.622266

A practical update on the use of bortezomib in the management of multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.622266

Reversibility of symptomatic peripheral neuropathy with bortezomib in the phase III APEX trial in relapsed multiple myeloma: impact of a dose-modification guideline

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.622266

Risk factors for, and reversibility of, peripheral neuropathy associated with bortezomib-melphalan-prednisone in newly diagnosed patients with multiple myeloma: subanalysis of the phase 3 VISTA study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.622266

Efficacy and safety of once-weekly bortezomib in multiple myeloma patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.622266

Analysis of herpes zoster events among bortezomib-treated patients in the phase III APEX study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.622266

Phase II clinical experience with the novel proteasome inhibitor bortezomib in patients with indolent non-Hodgkin's lymphoma and mantle cell lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.622266

Fewer bone disease events, improvement in bone remodeling, and evidence of bone healing with bortezomib plus melphalan-prednisone vs. melphalan-prednisone in the phase III VISTA trial in multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.622266

10.1517/14656566.2011.622266

21 January 2018

Identifiers

DOI

1 reference

25 August 2017

1 reference